---
title: "Varegacestat (AL102) in Desmoid tumors: AL102-501"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: AL102-501. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 13 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence/al102-501"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: AL102-501

<a id="heading-3.1.4"></a>

## 3.1.4 AL102-501

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Effect of itraconazole on varegacestat pharmacokinetics in healthy participants

> “A Phase 1, Open-Label, Fixed Sequence, 1-way Crossover Study Examining the Effect of Itraconazole on the Pharmacokinetics, Safety and Tolerability After Varegacestat Single Dose Administration to Healthy Participants”
> “Effect of itraconazole on the PK of varegacestat in healthy participants.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Registry status, dates, and site

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “AL102-501” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2024-11-11” |
| Primary completion (actual) | “2024-12-30” |
| Study completion (actual) | “2025-05-07” |
| First posted | “2024-11-07” |
| Last update posted | “2025-05-11” |
| Site | “Celerion”; “Tempe” |

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Open-label, fixed-sequence, two-period drug-drug interaction study

> “This is an open label, fixed sequence, 1-way crossover drug-drug interaction (DDI) study in healthy participants.”
> “This is a 2-period study. In period 1 a single dose of varegacestat will be administered with PK evaluated predose and up to 192 hours postdose. There will be a 14 -day washout between period 1 and period 2.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-3.1.4.3-2"></a>

#### Registry design fields

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
| Keywords | “Drug-Drug Interaction”; “Pharmacokinetics” |

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Healthy adults aged 18 to 55 years

> “Healthy, adult, male or female (of non-childbearing potential only), 18 to 55 years of age, inclusive, at the screening visit.”
> “Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs, as deemed by the PI or designee”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-3.1.4.4-2"></a>

#### Exclusion criteria

> “History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.”
> “History of any illness that, in the opinion of the PI or designee might confound the results of the study or poses an additional risk to the participant by their participation in the study.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Single varegacestat dose alone and with itraconazole 200 mg

> “Period 1: varegacestat administration for PK followed by Period 2: itraconazole and varegacestat administration for PK and DDI”
> “Itraconazole (200 mg)”
> “In period 2, itraconzole will be administered once daily for 18 consecutive days. Beginning on Day 4 of Period 2 a single dose of varegacestat will be administered 30 minutes after itraconazole dosing.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Primary endpoints: varegacestat AUC, Cmax, and Tmax with and without itraconazole

> “AUC0-t for varegacestat administered with and without itraconazole.”
> “AUC0-inf for varegacestat administered with and without itraconazole.”
> “Cmax for varegacestat administered with and without itraconazole.”
> “Tmax for varegacestat administered with and without itraconazole.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-3.1.4.6.1-2"></a>

##### Pharmacokinetic sampling for varegacestat and its metabolite

> “Blood samples for PK will be collected prior to varegacestat dosing and up to 744 hours post varegacestat dosing for varegacestat and its metabolite.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-3.1.4.6.1-3"></a>

##### Secondary endpoints: safety, tolerability, and itraconazole trough concentrations

> “Number of subjects who experience treatment-emergent adverse events (TEAEs)”
> “Number of subjects who experience 12-lead ECG abnormalities”
> “Ctrough of itraconazole and hydroxy-itraconazole in combination with varegacestat in healthy participants.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-3.1.4.6.1-4"></a>

##### Strong CYP3A4 inhibitors prohibited in the first-in-human study

> “The prohibited concomitant medications included herbal supplements, medications causing Torsades de Pointes, strong inhibitors or inducers of CYP3A4 or P-gp, and sensitive substrates of CYP3A4 with a narrow therapeutic window.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Actual enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (actual) | “22” |

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

- AL102-501 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2024-12-30, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of itraconazole on varegacestat exposure is unknown from public sources.
- The study is an open-label, single-group, fixed-sequence design in 22 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. Each participant received a single dose of varegacestat alone and then with itraconazole, so the results apply to single-dose exposure in healthy adults.
- The registry record does not state the varegacestat dose given.

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
